A Phase 3 interventional study of 13vPnC and Hib in Pneumococcal Infections and Pneumococcal Conjugate Vaccine, sponsored by Pfizer. Completed at 2 sites in China. Open to participants aged 42 Days to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-05.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 9th largest by enrollment, is one of 6 that started in 2018, is one of 19 in phase 3, and was the 32nd registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 42 Days to 5 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 6 started in 2018.
This study's enrollment of 936 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 21st largest by enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2018, is one of 33 in phase 3, and was the 42nd registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. Participants in cohort 1 will receive each dose of 13vPnC in months 2, 4 and 6, and then a booster dose during months 12-15. 2. Participants in cohort 2 will receive first dose dose 13vPnC at the age of months 7(included) to months 12 (less than months 12), and the second dose will be given at least 28 days after first dose, and the third dose will be months 12 to 15 (and at least 56 days after the second dose). 3. Participants in cohort 3 will receive the first dose of 13vPnC during 1 (included) to 2 years (less than 2 years of age) of age, and the second dose will be given at least 56 days after first dose. 4. Participants in cohort 4 will receive only one dose at the age of 2 (included) to 6 (less than 6 years of age) years of age.
Biological: 13vPnC
1. No participants in cohort 1 will receive Hib vaccine. 2. Participants in cohort 2 will receive the first dose of Hib vaccine at the age of months 7 (included) to 12 (less than 12 months), and the second dose will be given at least 28 days after the first dose, the third dose will following local practice or national recommendation at the discretion of the investigator. 3. Participants in cohorts 3 and 4 will receive the only one dose Hib vaccine at the age of 1 (included) to 6 (less than 6 years) years of age.
Biological: Hib
The Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of the Pneumococcal Serotypes Measured in Cohorts 2, 3 and 4 Compared to IgG GMCs Measured in Cohort 1
Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken 1 month after the infant series in Cohort 1 and the last dose 13vPnC in Cohorts 2, 3, 4. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
Time frame: Cohort 1: 1 month after the 3rd dose of 13vPnC (infant series dose). Cohort 2, 3, 4: 1 month after the last dose of 13vPnC.
Number of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 2
Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (decreased appetite, drowsiness and irritability) were recorded for 7 days after each investigational product vaccination.
Time frame: Within 7 Days After Each Vaccination
Number of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 3
Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (decreased appetite, drowsiness and irritability) were recorded for 7 days after each investigational product vaccination.
Time frame: Within 7 Days After Each Vaccination
Number of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 4
Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (fatigue, headache, vomiting, diarrhea, muscle pain and joint pain) were recorded for 7 days after each investigational product vaccination.
Time frame: Within 7 Days After Each Vaccination
Number of Participants With Adverse Event (AE) From the Signing of the Informed Consent Document (ICD) to 1 Month After the Last Vaccination in Cohorts 2, 3, 4
An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.
Time frame: From the signing of ICD to 1 month after the last vaccination (13vPnC or Hib) in Cohort 2, 3 and 4.
Number of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From 1 Month to 6 Months After the Last Vaccination in Cohorts 2, 3, 4
Number of participants with NDCMCs from 1 month after the last study vaccination (13vPnC or Hib vaccine) to 6 months after the last study vaccination in Cohorts 2, 3, and 4. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
Time frame: From 1 month to 6 months (5 months) after the last vaccination in Cohorts 2,3,4.
Number of Participants With SAE From the Signing of the ICD to 6 Months After the Last Vaccination in Cohorts 2, 3, 4
An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.
Time frame: From the signing of ICD to 6 month after the last vaccination (13vPnC or Hib) in Cohorts 2, 3 and 4.
The Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Each of the Pneumococcal Serotypes Measured in Cohorts 2, 3 and 4 Compared to IgG GMTs Measured in Cohort 1.
Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of about 50 participants receiving 13vPnC from the blood samples taken 1 month after the infant series in Cohort 1 and the last 13vPnC vaccination in each of the 3 cohorts. GMT and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.
Time frame: Cohort 1: 1 month after the 3rd dose of 13vPnC. Cohort 2, 3, 4: 1 month after the last dose of 13vPnC.
The Serotype-specific IgG GMCs for Each of the Pneumococcal Serotypes in Cohorts 2, 3, 4 Vaccinated With 13 vPnC Compared to Cohorts 2, 3 and 4 Vaccinated With Hib Vaccine.
Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken before vaccination and 1 month after vaccination in each of the 3 cohorts. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.
Time frame: Cohort 2, 3, 4: Before Vaccination and 1 Month After the Last Dose
The Serotype-specific OPA GMT for Each of the Pneumococcal Serotypes in Cohorts 2, 3, 4 Vaccinated With 13 vPnC Compared to Cohorts 2, 3 and 4 Vaccinated With Hib Vaccine.
Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of approximately 50 participants receiving 13vPnC and approximately 25 participants receiving Hib vaccine from the blood samples taken before vaccination and 1 month after the last 13vPnC vaccination in each of the 3 cohorts.
Time frame: Cohort 2, 3, 4: Before Vaccination and 1 Month After the Last Dose
Percentage of Participants Achieving Pneumococcal Serotype-specific IgG Concentration ≥0.35 mcg/mL for 1 Month After the Last Vaccination in Cohorts 2,3,4 (13vPnC and Hib Vaccine) and 1 Month After the Infant Series in Cohort 1 (13vPnC).
Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken 1 month after the infant series in Cohort 1 and the last dose of vaccination (13vPnC or Hib vaccine) in Cohorts 2, 3, 4.
Time frame: Cohort 1: 1 month after the 3rd dose of 13vPnC. Cohorts 2, 3, 4: 1 month after the last dose of 13vPnC and Hib Vaccine.
Percentage of Participants Achieving Serotype-specific Pneumococcal OPA Titer ≥ Lower Limit of Quantitation (LLOQ) for 1 Month After the Last Vaccination in Cohorts 2,3,4 (13vPnC and Hib Vaccine) and 1 Month After the Infant Series in Cohort 1 (13vPnC).
Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of about 50 participants receiving 13vPnC from the blood samples taken 1 month after the infant series in Cohort 1 and the last vaccination (13vPnC or Hib vaccine) in each of the 3 cohorts.
Time frame: Cohort 1: 1 month after the 3rd dose of 13vPnC. Cohorts 2, 3, 4: 1 month after the last dose of 13vPnC and Hib Vaccine.
Number of Participants With AE From the Signing of the ICD to 1 Month After the Infant Series in Cohort 1
An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.
Time frame: From the signing of ICD to 1 month after the 3rd dose of 13vPnC in Cohort 1.
Number of Participants With NDCMCs From 1 Month After Vaccination 3 to Vaccination 4 in Cohort 1
Number of Participants With NDCMCs from 1 month after vaccination 3 to vaccination 4 in Cohort 1. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
Time frame: From 1 month after Vaccination 3 to Vaccination 4.
Number of Participants With AE From Toddler Dose Until 1 Month After the Toddler Dose in Cohort 1
Number of Participants With AEs from vaccination 4 to 1 month after vaccination 4 in Cohort 1. An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.
Time frame: From Vaccination 4 to 1 month after Vaccination 4 in Cohort 1.
Number of Participants With NDCMCs From 1 Month to 6 Months After the Toddler Dose in Cohort 1
Number of Participants With NDCMCs from 1 month after vaccination 4 to 6 months after vaccination 4 in Cohort 1. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
Time frame: From 1 month to 6 months (5 months) after Vaccination 4 in Cohort 1.
Number of Participants With SAEs From the Signing of the ICD to 6 Months After the Toddler Dose in Cohort 1
Number of Participants With SAEs from the signing of the ICD to 6 months after vaccination 4. An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.
Time frame: From the Signing of the ICD to 6 Months After the Vaccination 4.
Serotype-specific IgG GMCs for Each of the Pneumococcal Serotypes in Cohort 1 at 12, 24, 36 and 48 Months After Last Vaccination in Cohort 1 (Infant Series)
Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken after last vaccination in Cohort 1. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.
Time frame: Cohort 1 (infant series): 12, 24, 36 and 48 Months After Last Vaccination in Cohort 1
This study presents results following completion of all vaccinations, including data from 6-month follow-up after the last study vaccination. This study was conducted in China.
| Milestone | Cohort 1 | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine |
|---|---|---|---|---|---|---|---|
| Started | 125 | 236 | 117 | 165 | 83 | 138 | 68 |
| Vaccination 1 | 125 | 236 | 117 | 165 | 83 | 138 | 68 |
| Vaccination 2 | 114 | 219 | 107 | 146 | 0 | 0 | 0 |
| Vaccination 3 | 111 | 214 | 0 | 0 | 0 | 0 | 0 |
| Vaccination 4 | 92 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 90 | 214 | 107 | 146 | 83 | 138 | 68 |
| Not completed | 35 | 22 | 10 | 19 | 0 | 0 | 0 |
| Withdrew: Noncompliance with investigational product | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 26 | 21 | 10 | 19 | 0 | 0 | 0 |
| Withdrew: Other | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine |
|---|---|---|---|---|---|---|---|
| Started | 90 | 214 | 107 | 146 | 83 | 138 | 68 |
| Completed | 89 | 201 | 98 | 137 | 76 | 131 | 67 |
| Not completed | 1 | 13 | 9 | 9 | 7 | 7 | 1 |
| Withdrew: Withdrawal by parent/guardian | 1 | 13 | 9 | 9 | 7 | 7 | 1 |
Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken 1 month after the infant series in Cohort 1 and the last dose 13vPnC in Cohorts 2, 3, 4. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
| mcg/mL | Cohort 1_Infant Series | Cohort 2_13vPnC | Cohort 3_13vPnC | Cohort 4_vPnC |
|---|---|---|---|---|
| Serotype 1 | 5.40 (4.43 to 6.58) | 3.75 (3.26 to 4.32) | 4.38 (3.75 to 5.11) | 4.40 (3.76 to 5.14) |
| Serotype 3 | 0.63 (0.54 to 0.75) | 1.19 (1.08 to 1.32) | 1.32 (1.16 to 1.51) | 1.12 (0.97 to 1.29) |
| Serotype 4 | 3.96 (3.24 to 4.84) | 2.97 (2.60 to 3.40) | 4.04 (3.48 to 4.68) | 4.47 (3.92 to 5.10) |
| Serotype 5 | 3.50 (2.91 to 4.19) | 3.07 (2.73 to 3.46) | 2.57 (2.26 to 2.92) | 2.92 (2.57 to 3.32) |
| Serotype 6A | 5.35 (4.44 to 6.44) | 3.12 (2.74 to 3.57) | 3.19 (2.69 to 3.78) | 3.39 (2.80 to 4.09) |
| Serotype 6B | 4.62 (3.76 to 5.69) | 2.20 (1.91 to 2.54) | 2.47 (2.06 to 2.96) | 2.96 (2.44 to 3.59) |
| Serotype 7F | 7.14 (6.00 to 8.50) | 5.73 (5.10 to 6.44) | 7.87 (6.90 to 8.96) | 7.08 (6.19 to 8.10) |
| Serotype 9V | 3.66 (2.99 to 4.50) | 2.24 (1.99 to 2.51) | 3.31 (2.90 to 3.77) | 3.68 (3.22 to 4.21) |
| Serotype 14 | 15.09 (11.39 to 20.00) | 10.89 (9.59 to 12.35) | 9.79 (8.40 to 11.41) | 6.94 (5.53 to 8.70) |
| Serotype 18C | 4.94 (4.11 to 5.94) | 2.25 (1.98 to 2.57) | 3.88 (3.25 to 4.64) | 5.60 (4.74 to 6.62) |
| Serotype 19A | 3.44 (2.85 to 4.16) | 3.62 (3.30 to 3.97) | 5.55 (4.86 to 6.34) | 11.62 (9.75 to 13.86) |
| Serotype 19F | 4.95 (3.91 to 6.26) | 4.50 (3.98 to 5.09) | 5.04 (4.28 to 5.92) | 5.44 (4.46 to 6.64) |
| Serotype 23F | 4.36 (3.23 to 5.88) | 2.04 (1.76 to 2.37) | 2.26 (1.90 to 2.67) | 2.80 (2.33 to 3.36) |
Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (decreased appetite, drowsiness and irritability) were recorded for 7 days after each investigational product vaccination.
| Participants | Cohort 2_13vPnC_Vaccination 1 | Cohort 2_Hib Vaccine_Vaccination 1 | Cohort 2_13vPnC_Vaccination 2 | Cohort 2_Hib Vaccine_Vaccination 2 | Cohort 2_13vPnC_Vaccination 3 |
|---|---|---|---|---|---|
| Local Reactions | 66 | 18 | 20 | 14 | 4 |
| Systemic Events | 23 | 7 | 23 | 5 | 1 |
Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (decreased appetite, drowsiness and irritability) were recorded for 7 days after each investigational product vaccination.
| Participants | Cohort 3_13vPnC _Vaccination 1 | Cohort 3_Hib Vaccine_Vaccination 1 | Cohort 3_13vPnC _Vaccination 2 |
|---|---|---|---|
| Local Reactions | 45 | 10 | 9 |
| Systemic Events | 26 | 7 | 4 |
Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (fatigue, headache, vomiting, diarrhea, muscle pain and joint pain) were recorded for 7 days after each investigational product vaccination.
| Participants | Cohort 4_13vPnC_Vaccination 1 | Cohort 4_Hib Vaccine_Vaccination 1 |
|---|---|---|
| Local Reactions | 48 | 21 |
| Systemic Events | 17 | 10 |
An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.
| Participants | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine |
|---|---|---|---|---|---|---|
| Number of Participants With Adverse Event (AE) From the Signing of the Informed Consent Document (ICD) to 1 Month After the Last Vaccination in Cohorts 2, 3, 4 | 76 | 29 | 21 | 1 | 11 | 1 |
Number of participants with NDCMCs from 1 month after the last study vaccination (13vPnC or Hib vaccine) to 6 months after the last study vaccination in Cohorts 2, 3, and 4. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
| Participants | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine |
|---|---|---|---|---|---|---|
| Number of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From 1 Month to 6 Months After the Last Vaccination in Cohorts 2, 3, 4 | 0 | 0 | 0 | 0 | 0 | 0 |
An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.
| Participants | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine |
|---|---|---|---|---|---|---|
| Number of Participants With SAE From the Signing of the ICD to 6 Months After the Last Vaccination in Cohorts 2, 3, 4 | 5 | 1 | 2 | 0 | 2 | 1 |
Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of about 50 participants receiving 13vPnC from the blood samples taken 1 month after the infant series in Cohort 1 and the last 13vPnC vaccination in each of the 3 cohorts. GMT and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.
| GMT | Cohort 1_Infant Series | Cohort 2_13vPnC | Cohort 3_13vPnC | Cohort 4_13vPnC |
|---|---|---|---|---|
| Serotype 1 | 201.7 (134.8 to 301.8) | 142.7 (103.4 to 196.9) | 93.3 (70.1 to 124.1) | 40.9 (31.3 to 53.4) |
| Serotype 3 | 112.9 (82.5 to 154.4) | 249.0 (205.7 to 301.5) | 332.3 (273.3 to 404.1) | 244.8 (192.0 to 312.1) |
| Serotype 4 | 1857.8 (1264.8 to 2728.8) | 2172.2 (1740.7 to 2710.7) | 2682.8 (2210.4 to 3256.2) | 4236.3 (3489.6 to 5142.8) |
| Serotype 5 | 645.9 (452.6 to 921.8) | 286.3 (214.5 to 382.0) | 164.5 (131.5 to 205.7) | 79.3 (57.7 to 109.0) |
| Serotype 6A | 5996.2 (4337.5 to 8289.3) | 6042.7 (4830.2 to 7559.6) | 7661.8 (6116.0 to 9598.4) | 5849.3 (4364.0 to 7840.2) |
| Serotype 6B | 2331.6 (1481.3 to 3670.0) | 2181.6 (1350.1 to 3525.2) | 4986.3 (3717.6 to 6687.9) | 3775.2 (2825.1 to 5044.9) |
| Serotype 7F | 10413.4 (7373.1 to 14707.3) | 10234.6 (8612.2 to 12162.8) | 14963.5 (12367.6 to 18104.4) | 17107.3 (13842.7 to 21141.8) |
| Serotype 9V | 5386.5 (3634.0 to 7984.3) | 4154.1 (3358.6 to 5138.0) | 7220.1 (5620.9 to 9274.2) | 10533.5 (7811.9 to 14203.4) |
| Serotype 14 | 2859.4 (1688.9 to 4899.3) | 4108.0 (3342.6 to 5048.8) | 6885.4 (5642.6 to 8402.0) | 7504.5 (5718.2 to 9848.9) |
| Serotype 18C | 2677.9 (2000.3 to 3585.0) | 1486.6 (1124.6 to 1965.2) | 1890.4 (1429.0 to 2500.6) | 2111.9 (1630.6 to 2735.2) |
| Serotype 19A | 1677.3 (1159.9 to 2425.5) | 2611.3 (2071.6 to 3291.6) | 3560.0 (2867.8 to 4419.1) | 3055.1 (2154.1 to 4333.1) |
| Serotype 19F | 744.4 (506.7 to 1093.6) | 1158.4 (937.0 to 1432.1) | 1854.0 (1520.3 to 2260.8) | 1629.7 (1292.9 to 2054.2) |
| Serotype 23F | 3833.2 (2216.2 to 6630.1) | 5640.0 (3590.5 to 8859.4) | 6693.6 (4464.2 to 10036.4) | 4234.7 (2916.1 to 6149.5) |
Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken before vaccination and 1 month after vaccination in each of the 3 cohorts. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.
| mcg/mL | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine |
|---|---|---|---|---|---|---|
| Serotype 1 - Before Vaccination | 0.02 (0.01 to 0.02) | 0.02 (0.01 to 0.03) | 0.07 (0.05 to 0.09) | 0.07 (0.05 to 0.10) | 0.18 (0.14 to 0.22) | 0.21 (0.15 to 0.28) |
| Serotype 1 - 1 Month After the Last Dose | 3.75 (3.26 to 4.32) | 0.04 (0.03 to 0.06) | 4.38 (3.75 to 5.11) | 0.07 (0.04 to 0.11) | 4.40 (3.76 to 5.14) | 0.16 (0.12 to 0.23) |
| Serotype 3 - Before Vaccination | 0.03 (0.03 to 0.04) | 0.03 (0.02 to 0.04) | 0.07 (0.05 to 0.09) | 0.07 (0.05 to 0.09) | 0.14 (0.10 to 0.18) | 0.13 (0.08 to 0.22) |
| Serotype 3 - 1 Month After the Last Dose | 1.19 (1.08 to 1.32) | 0.04 (0.03 to 0.05) | 1.32 (1.16 to 1.51) | 0.09 (0.06 to 0.13) | 1.12 (0.97 to 1.29) | 0.12 (0.07 to 0.20) |
| Serotype 4 - Before Vaccination | 0.01 (0.01 to 0.01) | 0.01 (0.01 to 0.01) | 0.03 (0.02 to 0.04) | 0.04 (0.03 to 0.06) | 0.07 (0.05 to 0.10) | 0.07 (0.05 to 0.11) |
| Serotype 4 - 1 Month After the Last Dose | 2.97 (2.60 to 3.40) | 0.02 (0.01 to 0.02) | 4.04 (3.48 to 4.68) | 0.03 (0.02 to 0.05) | 4.47 (3.92 to 5.10) | 0.06 (0.04 to 0.08) |
| Serotype 5 - Before Vaccination | 0.38 (0.34 to 0.43) | 0.36 (0.31 to 0.42) | 0.69 (0.60 to 0.78) | 0.63 (0.54 to 0.74) | 1.04 (0.92 to 1.17) | 0.97 (0.83 to 1.13) |
| Serotype 5 - 1 Month After the Last Dose | 3.07 (2.73 to 3.46) | 0.51 (0.43 to 0.61) | 2.57 (2.26 to 2.92) | 0.74 (0.62 to 0.88) | 2.92 (2.57 to 3.32) | 0.89 (0.73 to 1.07) |
| Serotype 6A - Before Vaccination | 0.15 (0.13 to 0.18) | 0.16 (0.13 to 0.20) | 0.30 (0.26 to 0.35) | 0.36 (0.30 to 0.42) | 0.79 (0.68 to 0.93) | 0.79 (0.64 to 0.97) |
| Serotype 6A - 1 Month After the Last Dose | 3.12 (2.74 to 3.57) | 0.20 (0.15 to 0.26) | 3.19 (2.69 to 3.78) | 0.42 (0.34 to 0.51) | 3.39 (2.80 to 4.09) | 0.80 (0.65 to 0.98) |
| Serotype 6B - Before Vaccination | 0.15 (0.12 to 0.17) | 0.15 (0.11 to 0.19) | 0.30 (0.26 to 0.35) | 0.35 (0.30 to 0.41) | 0.80 (0.69 to 0.94) | 0.70 (0.58 to 0.84) |
| Serotype 6B - 1 Month After the Last Dose | 2.20 (1.91 to 2.54) | 0.21 (0.16 to 0.26) | 2.47 (2.06 to 2.96) | 0.38 (0.32 to 0.46) | 2.96 (2.44 to 3.59) | 0.62 (0.49 to 0.79) |
| Serotype 7F - Before Vaccination | 0.03 (0.03 to 0.04) | 0.03 (0.02 to 0.04) | 0.10 (0.08 to 0.12) | 0.11 (0.08 to 0.15) | 0.25 (0.21 to 0.31) | 0.25 (0.18 to 0.33) |
| Serotype 7F - 1 Month After the Last Dose | 5.73 (5.10 to 6.44) | 0.05 (0.03 to 0.07) | 7.87 (6.90 to 8.96) | 0.13 (0.09 to 0.20) | 7.08 (6.19 to 8.10) | 0.21 (0.16 to 0.29) |
| Serotype 9V - Before Vaccination | 0.13 (0.11 to 0.16) | 0.16 (0.12 to 0.22) | 0.25 (0.20 to 0.31) | 0.27 (0.23 to 0.33) | 0.55 (0.47 to 0.65) | 0.41 (0.31 to 0.55) |
| Serotype 9V - 1 Month After the Last Dose | 2.24 (1.99 to 2.51) | 0.20 (0.14 to 0.27) | 3.31 (2.90 to 3.77) | 0.34 (0.26 to 0.43) | 3.68 (3.22 to 4.21) | 0.45 (0.37 to 0.54) |
| Serotype 14 - Before Vaccination | 0.03 (0.02 to 0.04) | 0.02 (0.02 to 0.03) | 0.03 (0.03 to 0.05) | 0.05 (0.03 to 0.09) | 0.19 (0.12 to 0.29) | 0.20 (0.11 to 0.36) |
| Serotype 14 - 1 Month After the Last Dose | 10.89 (9.59 to 12.35) | 0.02 (0.02 to 0.03) | 9.79 (8.40 to 11.41) | 0.07 (0.04 to 0.11) | 6.94 (5.53 to 8.70) | 0.20 (0.11 to 0.36) |
| Serotype 18C - Before Vaccination | 0.01 (0.01 to 0.01) | 0.01 (0.01 to 0.02) | 0.04 (0.03 to 0.06) | 0.05 (0.04 to 0.08) | 0.20 (0.15 to 0.27) | 0.20 (0.12 to 0.29) |
| Serotype 18C - 1 Month After the Last Dose | 2.25 (1.98 to 2.57) | 0.02 (0.01 to 0.03) | 3.88 (3.25 to 4.64) | 0.07 (0.04 to 0.12) | 5.60 (4.74 to 6.62) | 0.18 (0.11 to 0.29) |
| Serotype 19A - Before Vaccination | 0.36 (0.31 to 0.41) | 0.38 (0.31 to 0.46) | 0.65 (0.55 to 0.76) | 0.69 (0.58 to 0.83) | 1.72 (1.46 to 2.02) | 1.44 (1.13 to 1.83) |
| Serotype 19A - 1 Month After the Last Dose | 3.62 (3.30 to 3.97) | 0.50 (0.41 to 0.60) | 5.55 (4.86 to 6.34) | 0.88 (0.71 to 1.10) | 11.62 (9.75 to 13.86) | 1.33 (1.04 to 1.70) |
| Serotype 19F - Before Vaccination | 0.08 (0.07 to 0.11) | 0.11 (0.08 to 0.16) | 0.23 (0.18 to 0.29) | 0.23 (0.17 to 0.31) | 0.62 (0.49 to 0.78) | 0.57 (0.41 to 0.80) |
| Serotype 19F - 1 Month After the Last Dose | 4.50 (3.98 to 5.09) | 0.13 (0.09 to 0.19) | 5.04 (4.28 to 5.92) | 0.27 (0.18 to 0.39) | 5.44 (4.46 to 6.64) | 0.53 (0.38 to 0.73) |
| Serotype 23F - Before Vaccination | 0.11 (0.10 to 0.13) | 0.11 (0.09 to 0.14) | 0.19 (0.17 to 0.23) | 0.22 (0.19 to 0.26) | 0.54 (0.46 to 0.64) | 0.45 (0.35 to 0.57) |
| Serotype 23F - 1 Month After the Last Dose | 2.04 (1.76 to 2.37) | 0.17 (0.14 to 0.21) | 2.26 (1.90 to 2.67) | 0.27 (0.22 to 0.34) | 2.80 (2.33 to 3.36) | 0.44 (0.34 to 0.56) |
Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of approximately 50 participants receiving 13vPnC and approximately 25 participants receiving Hib vaccine from the blood samples taken before vaccination and 1 month after the last 13vPnC vaccination in each of the 3 cohorts.
| GMT | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine |
|---|---|---|---|---|---|---|
| Serotype 1 - Before Vaccination | 4.1 (3.9 to 4.4) | 4.2 (3.8 to 4.6) | 4.0 (4.0 to 4.0) | 4.2 (3.8 to 4.7) | 4.6 (4.2 to 5.0) | 5.5 (4.5 to 6.7) |
| Serotype 1 - 1 Month After the Last Dose | 142.7 (103.4 to 196.9) | 4.9 (3.6 to 6.8) | 93.3 (70.1 to 124.1) | 4.8 (3.8 to 6.0) | 40.9 (31.3 to 53.4) | 4.4 (3.8 to 5.1) |
| Serotype 3 - Before Vaccination | 5.8 (5.0 to 6.7) | 6.7 (4.5 to 10.0) | 11.9 (8.6 to 16.5) | 11.3 (6.9 to 18.5) | 27.1 (19.2 to 38.4) | 40.0 (22.7 to 70.7) |
| Serotype 3 - 1 Month After the Last Dose | 249.0 (205.7 to 301.5) | 7.4 (4.9 to 11.3) | 332.3 (273.3 to 404.1) | 13.4 (7.7 to 23.4) | 244.8 (192.0 to 312.1) | 28.4 (16.2 to 49.7) |
| Serotype 4 - Before Vaccination | 5.5 (4.3 to 6.9) | 5.0 (3.6 to 6.9) | 6.3 (4.8 to 8.3) | 9.5 (5.6 to 16.2) | 23.4 (13.8 to 39.7) | 15.9 (8.4 to 30.1) |
| Serotype 4 - 1 Month After the Last Dose | 2172.2 (1740.7 to 2710.7) | 10.3 (5.2 to 20.3) | 2682.8 (2210.4 to 3256.2) | 10.6 (5.7 to 19.6) | 4236.3 (3489.6 to 5142.8) | 19.2 (10.0 to 36.6) |
| Serotype 5 - Before Vaccination | 4.3 (3.8 to 4.9) | 4.0 (4.0 to 4.0) | 4.2 (3.9 to 4.4) | 4.1 (3.9 to 4.4) | 4.7 (4.1 to 5.3) | 4.2 (3.9 to 4.6) |
| Serotype 5 - 1 Month After the Last Dose | 286.3 (214.5 to 382.0) | 6.2 (4.0 to 9.7) | 164.5 (131.5 to 205.7) | 5.1 (3.6 to 7.2) | 79.3 (57.7 to 109.0) | 4.8 (4.0 to 5.8) |
| Serotype 6A - Before Vaccination | 5.0 (4.1 to 6.3) | 4.0 (4.0 to 4.0) | 6.9 (4.9 to 9.8) | 8.2 (4.7 to 14.3) | 45.5 (26.5 to 78.0) | 137.4 (63.3 to 297.9) |
| Serotype 6A - 1 Month After the Last Dose | 6042.7 (4830.2 to 7559.6) | 5.9 (4.0 to 8.8) | 7661.8 (6116.0 to 9598.4) | 17.8 (8.1 to 39.1) | 5849.3 (4364.0 to 7840.2) | 101.8 (45.7 to 226.8) |
| Serotype 6B - Before Vaccination | 5.1 (4.1 to 6.4) | 4.0 (4.0 to 4.0) | 8.2 (5.5 to 12.2) | 9.7 (5.6 to 16.8) | 53.6 (30.4 to 94.5) | 94.9 (43.0 to 209.3) |
| Serotype 6B - 1 Month After the Last Dose | 2181.6 (1350.1 to 3525.2) | 5.7 (3.8 to 8.6) | 4986.3 (3717.6 to 6687.9) | 20.2 (9.3 to 43.8) | 3775.2 (2825.1 to 5044.9) | 117.7 (51.9 to 267.1) |
| Serotype 7F - Before Vaccination | 63.0 (35.8 to 111.0) | 29.6 (12.4 to 70.4) | 195.8 (114.5 to 334.9) | 432.7 (213.8 to 875.8) | 1155.2 (852.6 to 1565.2) | 892.7 (515.3 to 1546.5) |
| Serotype 7F - 1 Month After the Last Dose | 10234.6 (8612.2 to 12162.8) | 94.0 (37.2 to 237.3) | 14963.5 (12367.6 to 18104.4) | 707.1 (361.9 to 1381.6) | 17107.3 (13842.7 to 21141.8) | 1090.7 (696.2 to 1708.8) |
| Serotype 9V - Before Vaccination | 9.3 (6.3 to 13.8) | 11.3 (5.9 to 21.5) | 59.5 (34.1 to 103.7) | 74.5 (31.0 to 179.0) | 458.9 (280.9 to 749.8) | 850.2 (469.4 to 1539.9) |
| Serotype 9V - 1 Month After the Last Dose | 4154.1 (3358.6 to 5138.0) | 20.6 (9.1 to 46.8) | 7220.1 (5620.9 to 9274.2) | 154.3 (69.9 to 340.9) | 10533.5 (7811.9 to 14203.4) | 795.1 (472.6 to 1337.6) |
| Serotype 14 - Before Vaccination | 9.8 (6.5 to 14.7) | 12.7 (6.2 to 26.3) | 30.0 (16.1 to 56.1) | 19.1 (8.5 to 43.0) | 132.6 (64.8 to 271.5) | 210.6 (87.7 to 505.5) |
| Serotype 14 - 1 Month After the Last Dose | 4108.0 (3342.6 to 5048.8) | 26.6 (11.4 to 62.3) | 6885.4 (5642.6 to 8402.0) | 39.0 (16.3 to 93.2) | 7504.5 (5718.2 to 9848.9) | 294.9 (126.5 to 687.1) |
| Serotype 18C - Before Vaccination | 4.3 (3.8 to 4.9) | 4.4 (3.8 to 5.1) | 6.1 (5.0 to 7.4) | 6.3 (4.4 to 8.9) | 12.7 (8.4 to 19.1) | 20.3 (10.0 to 41.3) |
| Serotype 18C - 1 Month After the Last Dose | 1486.6 (1124.6 to 1965.2) | 6.5 (4.1 to 10.3) | 1890.4 (1429.0 to 2500.6) | 7.9 (4.8 to 13.1) | 2111.9 (1630.6 to 2735.2) | 24.6 (12.1 to 50.1) |
| Serotype 19A - Before Vaccination | 5.3 (4.5 to 6.3) | 5.8 (4.1 to 8.1) | 11.1 (7.8 to 15.8) | 13.8 (7.8 to 24.3) | 60.3 (37.6 to 96.7) | 52.0 (24.2 to 111.6) |
| Serotype 19A - 1 Month After the Last Dose | 2611.3 (2071.6 to 3291.6) | 6.4 (4.6 to 8.9) | 3560.0 (2867.8 to 4419.1) | 15.5 (8.6 to 28.2) | 3055.1 (2154.1 to 4333.1) | 54.3 (27.6 to 107.1) |
| Serotype 19F - Before Vaccination | 4.3 (3.9 to 4.8) | 4.6 (3.7 to 5.7) | 6.2 (4.9 to 7.8) | 6.1 (4.5 to 8.3) | 24.7 (15.7 to 38.9) | 38.5 (18.1 to 81.8) |
| Serotype 19F - 1 Month After the Last Dose | 1158.4 (937.0 to 1432.1) | 5.9 (4.1 to 8.6) | 1854.0 (1520.3 to 2260.8) | 9.5 (5.6 to 16.2) | 1629.7 (1292.9 to 2054.2) | 41.1 (19.4 to 86.8) |
| Serotype 23F - Before Vaccination | 5.1 (4.1 to 6.3) | 4.7 (3.4 to 6.4) | 15.0 (8.8 to 25.6) | 11.1 (5.6 to 22.0) | 106.0 (59.5 to 188.9) | 70.5 (29.5 to 168.3) |
| Serotype 23F - 1 Month After the Last Dose | 5640.0 (3950.5 to 8859.4) | 20.2 (8.5 to 47.7) | 6693.6 (4464.2 to 10036.4) | 19.4 (8.8 to 42.8) | 4234.7 (2916.1 to 6149.5) | 97.2 (40.8 to 231.2) |
Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken 1 month after the infant series in Cohort 1 and the last dose of vaccination (13vPnC or Hib vaccine) in Cohorts 2, 3, 4.
| Percentage of Participants | Cohort 1_Infant Series | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine |
|---|---|---|---|---|---|---|---|
| Serotype 1 | 100.0 (95.0 to 100.0) | 99.4 (96.9 to 100.0) | 4.2 (0.9 to 11.7) | 97.6 (93.3 to 99.5) | 10.4 (4.6 to 19.4) | 99.2 (95.8 to 100.0) | 23.9 (14.3 to 35.9) |
| Serotype 3 | 83.3 (72.7 to 91.1) | 97.7 (94.3 to 99.4) | 4.2 (0.9 to 11.7) | 94.5 (89.0 to 97.8) | 11.7 (5.5 to 21.0) | 98.5 (94.6 to 99.8) | 19.4 (10.8 to 30.9) |
| Serotype 4 | 100.0 (95.0 to 100.0) | 99.4 (96.9 to 100.0) | 5.6 (1.5 to 13.6) | 97.6 (93.3 to 99.5) | 6.5 (2.1 to 14.5) | 99.2 (95.8 to 100.0) | 4.5 (0.9 to 12.5) |
| Serotype 5 | 100.0 (95.0 to 100.0) | 100.0 (97.9 to 100.0) | 69.4 (57.5 to 79.8) | 100.0 (97.1 to 100.0) | 85.7 (75.9 to 92.6) | 99.2 (95.8 to 100.0) | 88.1 (77.8 to 94.7) |
| Serotype 6A | 100.0 (95.0 to 100.0) | 97.7 (94.3 to 99.4) | 33.3 (22.7 to 45.4) | 97.6 (93.3 to 99.5) | 56.6 (44.7 to 67.9) | 100.0 (97.2 to 100.0) | 86.6 (76.0 to 93.7) |
| Serotype 6B | 100.0 (95.0 to 100.0) | 96.0 (92.0 to 98.4) | 23.6 (14.4 to 35.1) | 97.6 (93.3 to 99.5) | 50.6 (39.0 to 62.2) | 99.2 (95.8 to 100.0) | 77.6 (65.8 to 86.9) |
| Serotype 7F | 100.0 (95.0 to 100.0) | 99.4 (96.9 to 100.0) | 4.2 (0.9 to 11.9) | 98.4 (94.4 to 99.8) | 21.1 (12.5 to 31.9) | 99.2 (95.8 to 100.0) | 37.3 (25.8 to 50.0) |
| Serotype 9V | 100.0 (95.0 to 100.0) | 98.3 (95.1 to 99.6) | 31.9 (21.4 to 44.0) | 99.2 (95.7 to 100.0) | 40.8 (29.6 to 52.7) | 100.0 (97.2 to 100.0) | 59.7 (47.0 to 71.5) |
| Serotype 14 | 97.2 (90.3 to 99.7) | 99.4 (96.9 to 100.0) | 6.9 (2.3 to 15.5) | 98.4 (94.4 to 99.8) | 22.1 (13.4 to 33.0) | 100.0 (97.2 to 100.0) | 41.8 (29.8 to 54.5) |
| Serotype 18C | 100.0 (95.0 to 100.0) | 97.7 (94.3 to 99.4) | 5.6 (1.5 to 13.6) | 98.4 (94.4 to 99.8) | 15.6 (8.3 to 25.6) | 100.0 (97.2 to 100.0) | 40.9 (29.0 to 53.7) |
| Serotype 19A | 100.0 (95.0 to 100.0) | 100.0 (97.9 to 100.0) | 63.9 (51.7 to 74.9) | 100.0 (97.1 to 100.0) | 90.9 (82.2 to 96.3) | 100.0 (97.2 to 100.0) | 94.0 (85.4 to 98.3) |
| Serotype 19F | 98.6 (92.5 to 100.0) | 98.9 (96.0 to 99.9) | 29.2 (19.0 to 41.1) | 97.6 (93.3 to 99.5) | 44.2 (32.8 to 55.9) | 100.0 (97.2 to 100.0) | 70.1 (57.7 to 80.7) |
| Serotype 23F | 95.8 (88.3 to 99.1) | 95.5 (91.2 to 98.0) | 14.1 (7.0 to 24.4) | 97.6 (93.3 to 99.5) | 26.0 (16.6 to 37.2) | 96.9 (92.4 to 99.2) | 52.2 (39.7 to 64.6) |
Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of about 50 participants receiving 13vPnC from the blood samples taken 1 month after the infant series in Cohort 1 and the last vaccination (13vPnC or Hib vaccine) in each of the 3 cohorts.
| Percentage of Participants | Cohort 1_Infant Series | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine |
|---|---|---|---|---|---|---|---|
| Serotype 1 | 100.0 (90.5 to 100.0) | 96.6 (90.3 to 99.3) | 5.9 (0.7 to 19.7) | 96.2 (89.2 to 99.2) | 7.1 (1.5 to 19.5) | 95.8 (88.1 to 99.1) | 5.6 (0.7 to 18.7) |
| Serotype 3 | 100.0 (90.5 to 100.0) | 100.0 (95.8 to 100.0) | 29.4 (15.1 to 47.5) | 100.0 (95.4 to 100.0) | 38.1 (23.6 to 54.4) | 100.0 (94.9 to 100.0) | 80.6 (64.0 to 91.8) |
| Serotype 4 | 100.0 (90.5 to 100.0) | 100.0 (95.8 to 100.0) | 23.5 (10.7 to 41.2) | 100.0 (95.4 to 100.0) | 23.8 (12.1 to 39.5) | 100.0 (94.9 to 100.0) | 55.6 (38.1 to 72.1) |
| Serotype 5 | 100.0 (90.5 to 100.0) | 100.0 (95.8 to 100.0) | 14.7 (5.0 to 31.1) | 100.0 (95.4 to 100.0) | 4.8 (0.6 to 16.2) | 98.6 (92.4 to 100.0) | 11.1 (3.1 to 26.1) |
| Serotype 6A | 100.0 (90.5 to 100.0) | 100.0 (95.8 to 100.0) | 14.7 (5.0 to 31.1) | 100.0 (95.4 to 100.0) | 31.0 (17.6 to 47.1) | 100.0 (94.9 to 100.0) | 80.6 (64.0 to 91.8) |
| Serotype 6B | 100.0 (90.5 to 100.0) | 94.3 (87.1 to 98.1) | 11.8 (3.3 to 27.5) | 98.7 (93.1 to 100.0) | 35.7 (21.6 to 52.0) | 100.0 (94.9 to 100.0) | 80.6 (64.0 to 91.8) |
| Serotype 7F | 100.0 (90.5 to 100.0) | 100.0 (95.8 to 100.0) | 61.8 (43.6 to 77.8) | 100.0 (95.4 to 100.0) | 90.5 (77.4 to 97.3) | 100.0 (94.9 to 100.0) | 100.0 (90.3 to 100.0) |
| Serotype 9V | 100.0 (90.5 to 100.0) | 100.0 (95.8 to 100.0) | 41.2 (24.6 to 59.3) | 100.0 (95.4 to 100.0) | 76.2 (60.5 to 87.9) | 100.0 (94.9 to 100.0) | 97.2 (85.5 to 99.9) |
| Serotype 14 | 100.0 (90.5 to 100.0) | 100.0 (95.8 to 100.0) | 41.2 (24.6 to 59.3) | 100.0 (95.4 to 100.0) | 45.2 (29.8 to 61.3) | 100.0 (94.9 to 100.0) | 83.3 (67.2 to 93.6) |
| Serotype 18C | 100.0 (90.5 to 100.0) | 98.9 (93.8 to 100) | 14.7 (5.0 to 31.1) | 98.7 (93.1 to 100.0) | 21.4 (10.3 to 36.8) | 100.0 (94.9 to 100.0) | 52.8 (35.5 to 69.6) |
| Serotype 19A | 100.0 (90.5 to 100.0) | 100.0 (95.8 to 100.0) | 26.5 (12.9 to 44.4) | 100.0 (95.4 to 100.0) | 47.6 (32.0 to 63.6) | 100.0 (94.9 to 100.0) | 83.3 (67.2 to 93.6) |
| Serotype 19F | 97.3 (85.8 to 99.9) | 100.0 (95.8 to 100.0) | 17.6 (6.8 to 34.5) | 100.0 (95.4 to 100.0) | 26.2 (13.9 to 42.0) | 100.0 (94.9 to 100.0) | 63.9 (46.2 to 79.2) |
| Serotype 23F | 97.3 (85.8 to 99.9) | 95.4 (88.6 to 98.7) | 35.3 (19.7 to 53.5) | 96.2 (89.2 to 99.2) | 33.3 (19.6 to 49.5) | 97.2 (90.2 to 99.7) | 72.2 (54.8 to 85.8) |
An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.
| Participants | Cohort 1_Infant Series |
|---|---|
| Number of Participants With AE From the Signing of the ICD to 1 Month After the Infant Series in Cohort 1 | 14 |
Number of Participants With NDCMCs from 1 month after vaccination 3 to vaccination 4 in Cohort 1. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
| Participants | Cohort 1_Infant Series |
|---|---|
| Number of Participants With NDCMCs From 1 Month After Vaccination 3 to Vaccination 4 in Cohort 1 | 0 |
Number of Participants With AEs from vaccination 4 to 1 month after vaccination 4 in Cohort 1. An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.
| Participants | Cohort 1_ Toddler Dose |
|---|---|
| Number of Participants With AE From Toddler Dose Until 1 Month After the Toddler Dose in Cohort 1 | 5 |
Number of Participants With NDCMCs from 1 month after vaccination 4 to 6 months after vaccination 4 in Cohort 1. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
| Participants | Cohort 1 _Toddler Dose |
|---|---|
| Number of Participants With NDCMCs From 1 Month to 6 Months After the Toddler Dose in Cohort 1 | 0 |
Number of Participants With SAEs from the signing of the ICD to 6 months after vaccination 4. An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.
| Participants | Cohort 1 |
|---|---|
| Number of Participants With SAEs From the Signing of the ICD to 6 Months After the Toddler Dose in Cohort 1 | 9 |
Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken after last vaccination in Cohort 1. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.
| Microgram/milliliter | Cohort 1_Infant Series |
|---|---|
| Serotype 1: 12 Months After Last Vaccination in Cohort 1 | 1.35 (1.10 to 1.65) |
| Serotype 1: 24 Months After Last Vaccination in Cohort 1 | 0.88 (0.75 to 1.03) |
| Serotype 1: 36 Months After Last Vaccination in Cohort 1 | 0.77 (0.67 to 0.90) |
| Serotype 1: 48 Months After Last Vaccination in Cohort 1 | 0.79 (0.69 to 0.91) |
| Serotype 3: 12 Months After Last Vaccination in Cohort 1 | 0.27 (0.24 to 0.31) |
| Serotype 3: 24 Months After Last Vaccination in Cohort 1 | 0.22 (0.17 to 0.28) |
| Serotype 3: 36 Months After Last Vaccination in Cohort 1 | 0.18 (0.14 to 0.21) |
| Serotype 3: 48 Months After Last Vaccination in Cohort 1 | 0.19 (0.13 to 0.26) |
| Serotype 4: 12 Months After Last Vaccination in Cohort 1 | 1.10 (0.90 to 1.35) |
| Serotype 4: 24 Months After Last Vaccination in Cohort 1 | 0.54 (0.41 to 0.71) |
| Serotype 4: 36 Months After Last Vaccination in Cohort 1 | 0.58 (0.45 to 0.75) |
| Serotype 4: 48 Months After Last Vaccination in Cohort 1 | 0.32 (0.23 to 0.44) |
| Serotype 5: 12 Months After Last Vaccination in Cohort 1 | 1.56 (1.35 to 1.81) |
| Serotype 5: 24 Months After Last Vaccination in Cohort 1 | 1.03 (0.91 to 1.17) |
| Serotype 5: 36 Months After Last Vaccination in Cohort 1 | 1.03 (0.91 to 1.17) |
| Serotype 5: 48 Months After Last Vaccination in Cohort 1 | 1.19 (1.05 to 1.34) |
| Serotype 6A: 12 Months After Last Vaccination in Cohort 1 | 2.10 (1.71 to 2.59) |
| Serotype 6A: 24 Months After Last Vaccination in Cohort 1 | 1.40 (1.12 to 1.74) |
| Serotype 6A: 36 Months After Last Vaccination in Cohort 1 | 2.79 (2.04 to 3.80) |
| Serotype 6A: 48 Months After Last Vaccination in Cohort 1 | 3.06 (2.30 to 4.06) |
| Serotype 6B: 12 Months After Last Vaccination in Cohort 1 | 2.40 (1.94 to 2.95) |
| Serotype 6B: 24 Months After Last Vaccination in Cohort 1 | 2.12 (1.69 to 2.66) |
| Serotype 6B: 36 Months After Last Vaccination in Cohort 1 | 3.29 (2.57 to 4.21) |
| Serotype 6B: 48 Months After Last Vaccination in Cohort 1 | 3.73 (2.95 to 4.71) |
| Serotype 7F: 12 Months After Last Vaccination in Cohort 1 | 1.55 (1.31 to 1.82) |
| Serotype 7F: 24 Months After Last Vaccination in Cohort 1 | 0.77 (0.67 to 0.88) |
| Serotype 7F: 36 Months After Last Vaccination in Cohort 1 | 0.62 (0.56 to 0.70) |
| Serotype 7F: 48 Months After Last Vaccination in Cohort 1 | 0.53 (0.41 to 0.68) |
| Serotype 9V: 12 Months After Last Vaccination in Cohort 1 | 1.32 (1.11 to 1.57) |
| Serotype 9V: 24 Months After Last Vaccination in Cohort 1 | 0.88 (0.74 to 1.04) |
| Serotype 9V: 36 Months After Last Vaccination in Cohort 1 | 0.84 (0.72 to 0.99) |
| Serotype 9V: 48 Months After Last Vaccination in Cohort 1 | 0.95 (0.78 to 1.16) |
| Serotype 14: 12 Months After Last Vaccination in Cohort 1 | 2.77 (2.30 to 3.34) |
| Serotype 14: 24 Months After Last Vaccination in Cohort 1 | 2.03 (1.52 to 2.70) |
| Serotype 14: 36 Months After Last Vaccination in Cohort 1 | 2.49 (1.76 to 3.51) |
| Serotype 14: 48 Months After Last Vaccination in Cohort 1 | 2.14 (1.34 to 3.42) |
| Serotype 18C: 12 Months After Last Vaccination in Cohort 1 | 1.24 (1.07 to 1.43) |
| Serotype 18C: 24 Months After Last Vaccination in Cohort 1 | 0.72 (0.58 to 0.89) |
| Serotype 18C: 36 Months After Last Vaccination in Cohort 1 | 0.67 (0.54 to 0.81) |
| Serotype 18C: 48 Months After Last Vaccination in Cohort 1 | 0.60 (0.47 to 0.78) |
| Serotype 19A: 12 Months After Last Vaccination in Cohort 1 | 2.92 (2.29 to 3.74) |
| Serotype 19A: 24 Months After Last Vaccination in Cohort 1 | 3.52 (2.68 to 4.63) |
| Serotype 19A: 36 Months After Last Vaccination in Cohort 1 | 6.39 (4.79 to 8.51) |
| Serotype 19A: 48 Months After Last Vaccination in Cohort 1 | 7.53 (6.14 to 9.22) |
| Serotype 19F: 12 Months After Last Vaccination in Cohort 1 | 2.88 (2.32 to 3.57) |
| Serotype 19F: 24 Months After Last Vaccination in Cohort 1 | 2.73 (2.01 to 3.72) |
| Serotype 19F: 36 Months After Last Vaccination in Cohort 1 | 4.06 (2.92 to 5.66) |
| Serotype 19F: 48 Months After Last Vaccination in Cohort 1 | 3.51 (2.56 to 4.80) |
| Serotype 23F: 12 Months After Last Vaccination in Cohort 1 | 2.14 (1.76 to 2.59) |
| Serotype 23F: 24 Months After Last Vaccination in Cohort 1 | 1.72 (1.44 to 2.04) |
| Serotype 23F: 36 Months After Last Vaccination in Cohort 1 | 1.92 (1.58 to 2.34) |
| Serotype 23F: 48 Months After Last Vaccination in Cohort 1 | 2.15 (1.75 to 2.63) |
Collected over AE for Cohort 1: from the signing of the ICD to 1 month after Vaccination 3 and from Vaccination 4 to 1 month after Vaccination 4. AE for Cohorts 2,3,4: from the signing of the ICD to 1 month after the last study vaccination. SAE for Cohort 1,2,3,4: From the signing of the ICD to 6 months after the last study vaccination. See below for detailed vaccination timepoints in each cohort.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/125 (0%) | 9/125 (7.2%) | 13/125 (10.4%) |
| Cohort 2_13vPnC | 0/236 (0%) | 5/236 (2.1%) | 182/236 (77.1%) |
| Cohort 2_Hib Vaccine | 0/117 (0%) | 1/117 (0.9%) | 74/117 (63.2%) |
| Cohort 3_13vPnC | 0/165 (0%) | 2/165 (1.2%) | 99/165 (60%) |
| Cohort 3_Hib Vaccine | 0/83 (0%) | 0/83 (0%) | 26/83 (31.3%) |
| Cohort 4_13vPnC | 0/138 (0%) | 2/138 (1.4%) | 66/138 (47.8%) |
| Cohort 4_Hib Vaccine | 0/68 (0%) | 1/68 (1.5%) | 29/68 (42.6%) |
| Event | Cohort 1 | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine |
|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 7/125 | 1/236 | 0/117 | 1/165 | 0/83 | 1/138 | 1/68 |
| LymphadenitisBlood and lymphatic system disorders | 0/125 | 0/236 | 0/117 | 0/165 | 0/83 | 0/138 | 1/68 |
| PyrexiaGeneral disorders | 0/125 | 3/236 | 0/117 | 0/165 | 0/83 | 0/138 | 0/68 |
| Upper respiratory tract infectionInfections and infestations | 0/125 | 1/236 | 1/117 | 0/165 | 0/83 | 0/138 | 0/68 |
| Lower respiratory tract infection bacterialInfections and infestations | 1/125 | 0/236 | 0/117 | 0/165 | 0/83 | 0/138 | 0/68 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/125 | 0/236 | 0/117 | 0/165 | 0/83 | 0/138 | 0/68 |
| Otitis mediaInfections and infestations | 0/125 | 0/236 | 0/117 | 0/165 | 0/83 | 1/138 | 0/68 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/125 | 0/236 | 0/117 | 0/165 | 0/83 | 1/138 | 0/68 |
| Febrile convulsionNervous system disorders | 0/125 | 0/236 | 0/117 | 1/165 | 0/83 | 0/138 | 0/68 |
| Toxic encephalopathyNervous system disorders | 0/125 | 0/236 | 0/117 | 1/165 | 0/83 | 0/138 | 0/68 |
| Event | Cohort 1 | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine |
|---|---|---|---|---|---|---|---|
| Pyrexia (FEVER)General disorders | 0/125 | 121/236 | 37/117 | 55/165 | 16/83 | 20/138 | 16/68 |
| Erythema (REDNESS)Skin and subcutaneous tissue disorders | 1/125 | 68/236 | 27/117 | 42/165 | 10/83 | 36/138 | 15/68 |
| Swelling (SWELLING)General disorders | 0/125 | 38/236 | 5/117 | 21/165 | 3/83 | 27/138 | 16/68 |
| Tenderness (TENDERNESS)General disorders | 0/125 | 18/236 | 2/117 | 18/165 | 3/83 | 26/138 | 15/68 |
| PyrexiaGeneral disorders | 3/125 | 31/236 | 13/117 | 8/165 | 1/83 | 4/138 | 0/68 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/125 | 22/236 | 6/117 | 5/165 | 0/83 | 3/138 | 0/68 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/125 | 22/236 | 9/117 | 1/165 | 0/83 | 0/138 | 0/68 |
| Fatigue (FATIGUE)General disorders | 0/125 | 0/236 | 0/117 | 0/165 | 0/83 | 7/138 | 6/68 |
| Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders | 0/125 | 6/236 | 2/117 | 13/165 | 3/83 | 0/138 | 0/68 |
| Irritability (IRRITABILITY)Psychiatric disorders | 0/125 | 3/236 | 1/117 | 7/165 | 2/83 | 0/138 | 0/68 |
| Age, Continuous(Days) | Cohort 1 | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 49.1 ± 3.78 | 286.0 ± 41.06 | 285.9 ± 40.40 | — | — | — | — | 224.0 ± 109.94 |
| Age, Continuous(Days) | Cohort 1 | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| Median | 49.0 (43 to 56) | 284.0 (216 to 361) | 281.0 (217 to 360) | — | — | — | — | 260.0 (43 to 361) |
| Age, Continuous(Years) | Cohort 1 | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | — | — | — | 1.5 ± 0.27 | 1.6 ± 0.30 | 3.3 ± 1.11 | 3.3 ± 1.04 | 2.3 ± 1.18 |
| Age, Continuous(Years) | Cohort 1 | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| Median | — | — | — | 1.5 (1 to 2) | 1.6 (1 to 2) | 3.1 (2 to 6) | 3.3 (2 to 6) | 1.9 (1 to 6) |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 59 | 115 | 50 | 83 | 36 | 56 | 37 | 436 |
| Male | 66 | 121 | 67 | 82 | 47 | 82 | 31 | 496 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2_13vPnC | Cohort 2_Hib Vaccine | Cohort 3_13vPnC | Cohort 3_Hib Vaccine | Cohort 4_13vPnC | Cohort 4_Hib Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| Race_Asian | 125 | 236 | 117 | 165 | 83 | 138 | 68 | 932 |
| Ethnicity_Non-Hispanic/Non-Latino | 125 | 236 | 117 | 165 | 83 | 138 | 68 | 932 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2018 to primary completion in Aug 2021, 38 months.
Results were first posted in Apr 2024, 2 years 8 months after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 38 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine